Abbott Laboratories 2013 Annual Report Download - page 72

Download and view the complete annual report

Please find page 72 of the 2013 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 76

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76

ABBOTT 2013 ANNUAL REPORT
70
FINANCIAL REVIEW
delivery, and payment for health care products and services.
It is not possible to predict the extent to which Abbott or the
health care industry in general might be adversely affected by
these factors in the future. A more complete discussion of these
factors is contained in Item 1, Business, and Item 1A, Risk Factors,
to the Annual Report on Form 10-K.
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 —
A CAUTION CONCERNING FORWARD‑LOOKING STATEMENTS
Under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, Abbott cautions investors that
any forward-looking statements or projections made by Abbott,
including those made in this document, are subject to risks and
uncertainties that may cause actual results to differ materially
from those projected. Economic, competitive, governmental,
technological and other factors that may affect Abbott’s operations
are discussed in Item 1A, Risk Factors, to the Annual Report
on Form 10-K.
CONTINGENT OBLIGATIONS
Abbott has periodically entered into agreements in the ordinary
course of business, such as assignment of product rights, with
other companies, which has resulted in Abbott becoming second-
arily liable for obligations that Abbott was previously primarily
liable. Since Abbott no longer maintains a business relationship
with the other parties, Abbott is unable to develop an estimate of
the maximum potential amount of future payments, if any, under
these obligations. Based upon past experience, the likelihood of
payments under these agreements is remote. In addition, Abbott
periodically acquires a business or product rights in which Abbott
agrees to pay contingent consideration based on attaining certain
thresholds or based on the occurrence of certain events.
LEGISLATIVE ISSUES
Abbott’s primary markets are highly competitive and subject to
substantial government regulations throughout the world. Abbott
expects debate to continue over the availability, method of
Assuming $100 invested on 12/31/08 with dividends reinvested.
Abbott Laboratories
S&P 500 Index
S&P 500 Health Care Index
2008 20102009 2011 2012 2013
$250
$50
$100
$150
$200
PERFORMANCE GRAPH
This graph compares the change
in Abbott’s cumulative total shareholder
return on its common shares with the
Standard & Poor’s 500 Index and the
Standard & Poor’s 500 Health Care Index.
Assuming $100 was invested on December 31,
2007 with dividend reinvestment, Abbott’s
cumulative total shareholder return on its
common shares is 70%, compared to 44%
for the S&P 500 Index and 79% for the S&P
500 Healthcare Index.